Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Federico

Showing results (171-180 of 192) with videos related to

Pageof 20
Sort By:
Antiviral Therapy|February 14, 2019
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatmentMariantonietta Pisaturo, Mario Starace, Carmine Minichini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 9, 2019
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL studyMarcello Persico, Andrea Aglitti, Michele Milella, et al.
Journal of Clinical Medicine|October 16, 2024
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-AdministrationValerio Rosato, Riccardo Nevola, Marcello Dallio, et al.
Diagnostics (Basel, Switzerland)|February 13, 2026
Risk Factors for Inadequate Bowel Preparation Before Colonoscopy in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission: A Multicenter Retrospective Cohort StudyDavide Scalvini, Stiliano Maimaris, Elisa Stasi, et al.
World Journal of Gastroenterology|January 2, 2026
Sex-based differences in hepatitis delta virus infection: Insights from the Italian PITER hepatitis delta virus cohortBarbara Coco, Maria Giovanna Quaranta, Maria Elena Tosti, et al.
Hepatology International|April 13, 2020
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohortMaria Giovanna Quaranta, Luigina Ferrigno, Monica Monti, et al.
Journal of Hepatology|November 28, 2020
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scoresCristiana Bianco, Oveis Jamialahmadi, Serena Pelusi, et al.
Journal of Hepatology|April 11, 2022
Rare ATG7 genetic variants predispose patients to severe fatty liver diseaseGuido A Baselli, Oveis Jamialahmadi, Serena Pelusi, et al.
Free Radical Biology & Medicine|February 21, 2012
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trialCarmela Loguercio, Pietro Andreone, Ciprian Brisc, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatmentsJavier P Gisbert, Marco Romano, Javier Molina-Infante, et al.
Pageof 20

Showing results (171-180 of 192) with videos related to

Sort By:
Pageof 20
Antiviral Therapy|February 14, 2019
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatmentMariantonietta Pisaturo, Mario Starace, Carmine Minichini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 9, 2019
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL studyMarcello Persico, Andrea Aglitti, Michele Milella, et al.
Journal of Clinical Medicine|October 16, 2024
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-AdministrationValerio Rosato, Riccardo Nevola, Marcello Dallio, et al.
Diagnostics (Basel, Switzerland)|February 13, 2026
Risk Factors for Inadequate Bowel Preparation Before Colonoscopy in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission: A Multicenter Retrospective Cohort StudyDavide Scalvini, Stiliano Maimaris, Elisa Stasi, et al.
World Journal of Gastroenterology|January 2, 2026
Sex-based differences in hepatitis delta virus infection: Insights from the Italian PITER hepatitis delta virus cohortBarbara Coco, Maria Giovanna Quaranta, Maria Elena Tosti, et al.
Hepatology International|April 13, 2020
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohortMaria Giovanna Quaranta, Luigina Ferrigno, Monica Monti, et al.
Journal of Hepatology|November 28, 2020
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scoresCristiana Bianco, Oveis Jamialahmadi, Serena Pelusi, et al.
Journal of Hepatology|April 11, 2022
Rare ATG7 genetic variants predispose patients to severe fatty liver diseaseGuido A Baselli, Oveis Jamialahmadi, Serena Pelusi, et al.
Free Radical Biology & Medicine|February 21, 2012
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trialCarmela Loguercio, Pietro Andreone, Ciprian Brisc, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatmentsJavier P Gisbert, Marco Romano, Javier Molina-Infante, et al.
Pageof 20